Australia - English - Department of Health (Therapeutic Goods Administration)

plastic products imports - 15571 - cover, - a disposable plastic cover for use of a dental bite block for use in x-ray procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

plastic products imports - 35692 - endoscope element, obturator - a device with a distally rounded head or end that is placed into the sheath of a rigid endoscope intended to fill out the sheath's lumen, thereby assisting its insertion into the body and protecting against adverse damage to the patient.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dow agrosciences australia limited - fenbuconazole - suspension concentrate - fenbuconazole thiazole active 240.0 g/l - fungicide - banana | nectarine | wheat | incl.interplanted with avocado - black sigatoka | brown rot | leaf spot or yellow sigatoka on banana | stripe rust | sigatoka | yellow rust | yellow sigatoka

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

four seasons agribusiness pty ltd - moxidectin - parenteral liquid/solution/suspension - moxidectin anthelmintic active 20.0 g/l - parasiticides

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

four seasons agribusiness pty ltd - moxidectin - parenteral liquid/solution/suspension - moxidectin anthelmintic active 20.0 g/l - parasiticides

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

four seasons agribusiness pty ltd - moxidectin; liquid hydrocarbon - topical solution/suspension - moxidectin anthelmintic active 5.0 g/l; liquid hydrocarbon solvent other 150.0 g/l - parasiticides

United States - English - NLM (National Library of Medicine)

winder laboratories, llc - phenazopyridine hydrochloride (unii: 0ewg668w17) (phenazopyridine - unii:k2j09emj52) - phenazopyridine hydrochloride 100 mg - phenazopyridine hcl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. the use of phenazopyridine hcl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and phenazopyridine hcl should be discontinued when symptoms are controlled. the analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. it is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. treatment of a urinary tract infection with phenazopyridine hcl should not exceed 2 days because there is a lack of evidence that the combined administration of 

United States - English - NLM (National Library of Medicine)

winder laboratories, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - based on a review of this drug by the national academy of sciences–national research council and/or other information, fda has classified the indications as follows: “possibly” effective: for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. may also be useful as adjunctive therapy in the treatment of duodenal ulcer. final classification of the less-than-effective indications requires further investigation. it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. phenohytro™ tablets are contraindicated in patients with glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable

United States - English - NLM (National Library of Medicine)

winder laboratories, llc - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o), vitamin a (unii: 81g40h8b0t) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), sodium ascorbate (unii: s033eh8359) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - supplementation of the diet with fluoride and ten essential vitamins. multivitamin with 1.0 mg fluoride chewable tablets provide fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. multivitamin with 0.5 mg fluoride chewable tablet s provide fluoride in tablet form for children 4-6 years of age where the water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. multivitamin with 0.25 mg fluoride chewable tablets provide fluoride in tablet form for children 4-6 years of age where the drinking water contains 0.3 through 0.6 ppm of fluoride. multivitamin with fluoride chewable tablets supply significant amounts of vitamins a, c, d, e, thiamine, riboflavin, niacin, vitamin b6, vitamin b12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. supplementation of the diet with fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. children using multivitamin with fluoride chewable tablets regularly should receive semiannual dental examinations. the regular brushing of teeth and attention to good oral hygiene practices are also essential. multivitamin with fluoride chewable tablets are prescription product for the clinical dietary management of metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins.

United States - English - NLM (National Library of Medicine)

winder laboratories llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate oral solution 2 mg/ml and 4 mg/ml is indicated for the management of: - adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 20 mg/ml is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients . limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions ( 5.2)], reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. pediatric use information is approved for hikma pharmaceuticals usa inc.'s morphine sulfate oral solution. however, due to hikma pharmaceuticals usa inc.'s marketing exclusivity